Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Andrew Davis

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

A.A. Davis1, W. Iams2, D. Chan3, M.S. Oh1, R.W. Lentz1, R. Srivas4, N. Lambert4, A. Robertson4, N. Peterman4, A. Shah4, T. Wilson4, J. Close4, P. George4, H. Wood4, B. Wong4, A. Tezcan4, J.C. Spinosa4, H. Tezcan4, Y.K. Chae5

Author affiliations

  • 1 Department Of Medicine, Northwestern University Feinberg School of Medicine, 60611 - Chicago/US
  • 2 Medicine, Vanderbilt University, 37240 - Nashville/US
  • 3 Tmpn, Cancer Care Associates, 90277 - Redondo Beach/US
  • 4 Lexent Bio, Inc., 94103 - San Francisco/US
  • 5 Department Of Medicine, Northwestern University Feinberg School of Medicine, Chicago/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3664

Background

Aberrant methylation changes are present in nearly all cancers. The goal of this study was to determine if changes in cfDNA methylation patterns during the course of treatment could predict non-response prior to routine imaging.

Methods

We prospectively collected clinical data and blood from 52 patients with advanced malignancies (25 lung, 11 breast, 16 other). Blood was drawn prior to start of a new treatment, after first cycle (median 23 days), and/or second cycle (median 43 days). We performed whole-genome (WG) bisulfite sequencing (median depth 18X) on plasma cfDNA to determine methylation levels. By tracking how methylation levels change across 19,710 regions throughout the genome, from baseline to subsequent timepoints, we classified patients as either progressors or non-progressors. Treatment response at first follow-up imaging (FUI) was determined by RECIST 1.1 or clinical assessment. Study endpoints were agreement with first FUI and progression-free survival (PFS) by cfDNA classification.

Results

The cohort consisted of 58% females and the median age was 71. Main treatment regimens were immuno- (22), chemo- (20), targeted- (7) or endocrine therapy (3). PFS was significantly shorter (log-rank p = 0.003) in patients classified as progressors by cfDNA (N = 10; median: 90 days) compared to non-progressors (42, median: 263 days). 6 out of 10 patients classified as cfDNA progressors were later confirmed to progress at first follow-up evaluation (60% positive predictive value). The cfDNA assay for these 6 patients preceded imaging and clinical evaluation by a median of 40 days. For the remaining patients, 39 of 42 did not progress (93% negative predictive value). Thus, sensitivity for the assay for identifying progression was 67% and specificity was 91%.

Conclusions

Our results show that WG cfDNA methylation change is a novel cancer signature with potential to identify patients whose treatment regimen is ineffective prior to imaging, and allow switching to a more effective alternative at an earlier time. Moreover, integrating methylation-based changes with information about genomic alterations may increase performance of cfDNA-based response monitoring.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Lexent Bio, Inc.

Disclosure

A.A. Davis: Travel / Accommodation / Expenses: Menarini Silicon Biosystems. W. Iams: Travel / Accommodation / Expenses, Clinical Trials Visit: EMD Serono. R. Srivas: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc. N. Lambert: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc.; Shareholder / Stockholder / Stock options: Sequenom. A. Robertson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc.; Full / Part-time employment, Prior employment: Color Genomics; Shareholder / Stockholder / Stock options, 2015-2018: Counsyl. N. Peterman: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc. A. Shah: Full / Part-time employment: Lexent Bio, Inc.; Shareholder / Stockholder / Stock options: Myriad. T. Wilson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc.; Shareholder / Stockholder / Stock options, Full / Part-time employment, Prior employment: Illumina; Shareholder / Stockholder / Stock options: Counsyl; Licensing / Royalties: Gen-Probe. J. Close: Full / Part-time employment: Lexent Bio, Inc. P. George: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc.; Shareholder / Stockholder / Stock options: Hologic. H. Wood: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc. B. Wong: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc. A. Tezcan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc. J.C. Spinosa: Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc.; Full / Part-time employment: San Diego Blood Bank; Advisory / Consultancy: Gestalt Diagnostics; Advisory / Consultancy: SonicHealthUSA. H. Tezcan: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Lexent Bio, Inc.; Shareholder / Stockholder / Stock options, 2015-2018: Counsyl. Y.K. Chae: Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Biodesix; Advisory / Consultancy: Counsyl; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Guardant Health; Advisory / Consultancy: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech; Advisory / Consultancy: ImmuneOncia; Advisory / Consultancy: Hanmi; Speaker Bureau / Expert testimony: Merck; Speaker Bureau / Expert testimony: Eli Lilly; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Lexent Bio; Research grant / Funding (institution): Freenome. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.